Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the efficacy of subcutaneous versus oral mu-opioid receptor antagonist therapy in opioid induced constipation that is refractory to other bowel regimens.


Clinical Trial Description

Opioid-induced constipation can lead to serious complications, including small bowel obstruction, fecal impaction, and bowel perforation. Not only are the medical complications potentially severe, patient quality of life can also be impacted. Two agents are currently available for opioid-induced constipation - oral and subcutaneous methylnaltrexone and oral naloxegol. Mechanistically, both agents antagonize the peripheral mu-opioid receptor in the gastrointestinal tract to decrease constipation without reversing the systemic analgesic effects of opiates. The literature currently available has evaluated the effectiveness of each agent, not the comparative effectiveness of these agents. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03523520
Study type Interventional
Source University of Missouri-Columbia
Contact
Status Completed
Phase Phase 4
Start date December 23, 2020
Completion date March 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT04294550 - Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
Recruiting NCT03316859 - Naloxegol and Opioid-induced Constipation Phase 2/Phase 3
Completed NCT02737059 - Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects Phase 1
Recruiting NCT02958566 - Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery Phase 4
Recruiting NCT04876508 - The Efficacy of Acupressure in Managing Opioid-induced Constipation N/A
Completed NCT04462211 - Constipation Bundle/Protocol and the Effect of Adherence in the Incidence of Constipation in Critically Ill Patients N/A